Recent trends in Management and Commerce

Vol: 6(2), 2025

REST Publisher; ISBN: 978-81-936097-6-7

Website: https://restpublisher.com/book-series/rmc/

DOI: https://doi.org/10.46632/rmc/6/2/6



Global Best Practices in Injectable Formulations Value Chain Management: Lessons for Emerging Markets

***Milind Bhimrao Khabale, Mahesh Laxmikant Abale, Shailesh Kasande**

Suryadatta Institute of Management and Mass Communication, Savitribai Phule Pune University, Pune, Maharashtra, India.

Corresponding Author Email: *milind.khabale@gmail.com*

Abstract: *Injectable formulations are central to contemporary healthcare, serving critical roles in oncology, immunology, chronic disease management, and emergency care. Their therapeutic value, however, depends not only on manufacturing quality but also on the integrity and efficiency of downstream value chain management. Failures in cold chain maintenance, inadequate traceability, and weak regulatory oversight have been linked to high wastage rates, counterfeit infiltration, and inequitable access, especially in emerging economies. This paper reviews global best practices in injectable formulations value chain management and analyses their relevance for adoption in resource constrained contexts. The methodology is based on secondary sources including peer reviewed academic studies, WHO and FDA guidelines, OECD policy briefs, and industry analyses from McKinsey, PwC, and Deloitte, complemented by case studies of Pfizer, Roche, Novartis, Sanofi, and Johnson & Johnson. The review identifies five critical best practice domains: serialization and digital traceability, cold chain resilience, Risk sharing partnerships, regulatory harmonization, and patient centric delivery systems. Case examples include the European Union's Falsified Medicines Directive, UNICEF-supported vaccine networks, FDA–EMA joint inspections, and oncology patient programs in the United States. Comparative tables highlight global cold chain wastage rates and serialization adoption patterns across regions. The findings suggest that while global practices are robust in ensuring safety, efficiency, and resilience, their adoption in emerging markets requires phased implementation, infrastructural investment, regional harmonization, and Public Private partnerships. The paper concludes with a best practice framework tailored for emerging economies, emphasizing hybrid distribution models, digital monitoring, and collaborative governance as pathways toward equitable access to life-saving injectable therapies.*

Keywords*: Value Chain Management, Injectable Formulations, Serialization, Cold chain resilience, Risk sharing partnerships, Regulatory harmonization, Patient centric models, Pharmaceutical Supply Chain,*

1. INTRODUCTION

The demand for injectable formulations has grown substantially over the past two decades, driven by the increasing prevalence of chronic illnesses such as diabetes, autoimmune disorders, and cancer, alongside the continued global need for vaccines and emergency medicines. Unlike oral solid dosage forms, which are relatively stable, injectables often require precise handling and stringent environmental control. Cold chain infrastructure commonly maintaining products at 2–8°C is indispensable, with advanced biologics sometimes requiring ultra-cold storage at –20°C or even –70°C. Breakdowns in this chain undermine therapeutic efficacy, compromise patient safety, and cause significant economic loss.

McKinsey (2020) estimated that the biopharma sector loses nearly USD 35 billion annually due to cold chain failures, while WHO (2017) reported that vaccine wastage in low- and middle-income countries frequently exceeds 20%. Such statistics underscore the critical role of value chain management in ensuring the integrity of injectables.

The pharmaceutical landscape, however, is diverse. In advanced economies, sophisticated infrastructure, harmonized regulation, and digital technologies allow supply chains to function with minimal wastage and strong resilience. By contrast, in emerging economies, supply chains remain fragmented, regulatory enforcement is

uneven, and investments in refrigerated logistics are insufficient. This divergence raises the central research problem: global best practices exist, but their adaptability to emerging markets is underexplored.

The purpose of this paper is therefore to review global best practices in injectable formulations value chain management and extract lessons for emerging markets. The guiding research questions are: What defines global best practice in this domain? Which practices are most transferable to resource constrained settings? How can a framework be developed to support gradual, context specific adoption?

2. LITERATURE REVIEW

The literature identifies several recurring themes in pharmaceutical supply chain management. One central area is serialization and traceability, pioneered through the European Union's Falsified Medicines Directive (EMA, 2018), which requires unique identifiers on all prescription medicines. Studies show that serialization reduces counterfeit risks and enhances supply chain transparency.

A second theme is cold chain resilience. McKinsey (2020) highlighted that biologics and vaccines account for nearly half of top selling pharmaceuticals, necessitating sophisticated refrigeration systems. UNICEF and Roche have collaborated on deploying insulated containers and IoT-based monitoring devices in Africa and Asia, reducing wastage rates by 10–15% (Roche, 2020).

Third, Risk sharing partnerships are increasingly emphasized. Novartis, for example, has negotiated distributor contracts where liability for cold chain failures is shared, ensuring aligned incentives for quality maintenance. Similarly, Gavi supported vaccine distribution networks in Africa illustrate how pooling risks across governments, donors, and private firms can improve accountability and financial sustainability.

Fourth, regulatory harmonization is recognized as a driver of efficiency. FDA–EMA joint inspections of pharmaceutical sites reduce duplication and foster mutual recognition of standards, while the International Council for Harmonisation (ICH) promotes convergence of quality requirements across regions.

Finally, patient centric delivery models are gaining traction, particularly in oncology. Johnson & Johnson has introduced direct-to-patient services in the United States, integrating medicine distribution with adherence support and education programs (J&J, 2019). These approaches reflect a broader trend toward supply chains that prioritize clinical outcomes alongside logistical efficiency.

In emerging economies, adaptations have begun. India's Electronic Vaccine Intelligence Network (eVIN) tracks vaccine stock and temperatures across more than 25,000 cold chain points, reducing wastage and improving forecasting (MoHFW, 2020). Brazil has piloted hybrid distribution systems to reach remote Amazonian regions, while South Africa has experimented with regional cold chain pooling through Public Private partnerships (South African Health Review, 2019). These examples illustrate both the potential and the constraints of applying global practices in resource-limited contexts.

3. RESEARCH OBJECTIVES & QUESTIONS

The objectives of this study are fourfold:

- To review global best practices in injectable formulations value chain management.
- To categorize these practices across domains such as technology, logistics, regulation, and stakeholder coordination.
- To assess their adaptability to emerging markets facing infrastructural and regulatory challenges.
- To propose a best practice framework for resource-limited settings.

The research questions are:

1. What constitutes global best practice in injectable value chains?
2. How can these practices be applied or modified in emerging markets?
3. Which lessons from global leaders are most transferable to contexts such as India, Brazil, and sub-Saharan Africa?
4. What framework can guide gradual, sustainable adoption in emerging economies?

4. METHODOLOGY

Research Design

This study adopts a **qualitative exploratory approach** grounded entirely in secondary data. Given that the global distribution of injectable formulations is already documented across multiple scholarly, regulatory, and industry sources, the methodological focus was not on generating primary data but on **integrating, classifying, and critically interpreting existing knowledge**. This approach is particularly suited for identifying global best practices and assessing their applicability to emerging market contexts.

Data Sources

The research process began with an extensive review of published academic literature sourced from **PubMed, Scopus, and ScienceDirect**. Studies were selected based on their relevance to pharmaceutical supply chains, cold chain logistics, serialization and traceability, regulatory harmonization, and patient-centric delivery models.

In addition to academic literature, significant emphasis was placed on **industry reports**, which provide comprehensive analyses of trends and practices. These included:

- *McKinsey's Pharma Logistics 2030*
- *Deloitte's Reimagine Cold Chain*
- *PwC's Reinventing Pharma Supply Chains*

To capture regulatory perspectives, guidance documents and policies from **WHO, FDA (United States), EMA (Europe), and CDSCO (India)** were reviewed for insights into compliance frameworks, enforcement mechanisms, and harmonization efforts.

Case Studies

To ensure practical grounding, case studies of leading pharmaceutical companies were incorporated:

- **Pfizer** – centralized logistics hubs in Europe
- **Roche** – oncology-focused hub-and-spoke distribution model
- **Novartis** – direct-to-hospital biologics distribution
- **Sanofi** – global vaccine partnerships
- **Johnson & Johnson** – oncology patient support programs

These examples were deliberately selected to reflect both the **diversity of approaches** and the **adaptability of models** across regions and therapeutic categories.

Analytical Strategy

The study employed **thematic synthesis** as the core analytical strategy:

1. **Categorization:** Data were organized into domains of best practice — technology and traceability, cold-chain resilience, risk-sharing partnerships, regulatory harmonization, and patient-centric models.
2. **Comparative Analysis:** Practices were examined across regions, distinguishing between those common in high-income countries and those adapted (or constrained) in emerging markets.
3. **Pattern Identification:** Convergences, divergences, and recurring lessons were identified to assess which practices had the highest transferability.

Adaptability Assessment

Special attention was given to **contextual factors** shaping the adoption of global practices in emerging markets, including:

- Infrastructural readiness
- Financial and resource constraints
- Regulatory enforcement capacity
- Policy environments and governance

Sources from **India, Brazil, South Africa, and sub-Saharan Africa** were reviewed to ground the adaptability analysis in real-world challenges and opportunities.

Reliability and Validity

To strengthen methodological rigor:

- **Triangulation** was ensured by drawing from academic studies, regulatory documents, and industry reports.
- **Contextual validation** was achieved by cross-checking global evidence against emerging market case studies.

- **Transparency** was maintained through explicit reporting of domains, coding categories, and case study selection.

Ethical Considerations
The study relied entirely on secondary, publicly available data. As such, no ethical clearance was required. Nevertheless, all sources were appropriately cited, and care was taken to avoid misinterpretation of findings.

Methodological Limitations
While reliance on secondary data limited the ability to capture real-time, ground-level experiences, the breadth and diversity of materials analyzed provided a robust foundation for synthesizing global lessons. The resulting best practice framework is therefore positioned as a conceptual guide for policymakers and industry leaders in emerging economies.

5. GLOBAL BEST PRACTICES: CATEGORIES & CASE EVIDENCE

Best practices in the management of value chains for injectable formulations have evolved in response to the increasing complexity of global pharmaceutical markets, the rise of biologics, and the heightened need for regulatory oversight. The literature and case studies reviewed in this study point consistently to five interconnected domains where global leaders have made substantial progress: technology and traceability, cold chain resilience, Risk sharing and partnerships, regulatory harmonization, and patient centric delivery systems. These categories reflect both the technological sophistication of high income countries and the adaptability of companies operating across diverse regulatory and infrastructural landscapes.

Technology and traceability represent one of the most important advances in securing pharmaceutical supply chains. Serialization and barcoding allow every unit of an injectable to be uniquely identified, ensuring that products can be tracked from the manufacturer to the point of administration. The European Union's Falsified Medicines Directive (EMA, 2018) stands as a landmark policy requiring serialization of all prescription medicines across member states. This has dramatically reduced the circulation of counterfeit drugs in Europe by enabling real-time authentication at the point of dispensing. Major global firms such as Pfizer and Novartis have adopted serialization globally, and both companies have piloted blockchain solutions to further strengthen transparency and trust within their value chains. These technologies not only secure supply but also generate valuable data for forecasting demand and managing recalls.

Cold Chain Resilience has also emerged as a cornerstone of injectable value chain management. With biologics and vaccines now constituting nearly half of top-selling medicines (McKinsey, 2020), maintaining precise temperature ranges during storage and transportation is critical. Roche, in collaboration with UNICEF, has invested in insulated containers and IoT-enabled monitoring devices for vaccine distribution in Africa and Asia, reporting reductions in wastage rates by up to 15 percent (Roche, 2020). UNICEF (2019) further documented improvements in equity of access when advanced cold chain technologies were combined with last-mile distribution partnerships. Such initiatives underline that cold chain integrity is not only a matter of product stability but also of global health equity.

Risk sharing and partnerships are increasingly shaping distribution models for injectables. Recognizing that no single stakeholder can manage all aspects of complex supply chains, global firms have begun entering strategic agreements that spread responsibility for cold chain failures and logistical bottlenecks. Novartis has pioneered contracts with distributors that make liability for cold chain breaches a shared obligation, aligning incentives across the value chain. Similarly, Gavi's vaccine alliance has shown how Public Private partnerships can ensure more equitable distribution, especially in low-income countries. By pooling risks, these models reduce the financial vulnerability of both manufacturers and governments while enhancing accountability for outcomes.

Regulatory harmonization is another domain where best practices are increasingly evident. Pharmaceutical supply chains are inherently global, yet regulatory requirements often differ across jurisdictions, creating inefficiencies and duplication. The FDA and EMA have attempted to bridge this gap through joint inspections of manufacturing and distribution sites, reducing redundancy while maintaining stringent oversight. The International Council for Harmonisation (ICH) has further contributed to the convergence of Good Manufacturing Practices (GMP), giving global firms a more predictable regulatory environment in which to operate. Such harmonization efforts demonstrate that efficiency gains can be achieved without undermining quality, provided that collaboration between regulatory authorities is sustained.

Patient centric models represent the newest frontier in value chain management. These approaches shift focus from logistics alone to the broader patient experience, recognizing that timely, safe, and supportive delivery of injectables can significantly influence clinical outcomes. Johnson & Johnson, for instance, has developed direct-to-patient delivery systems for oncology injectables in the United States, complemented by patient support programs that include adherence education and personalized counselling (Johnson & Johnson, 2019). By integrating delivery with care support, such models extend the value chain beyond distribution into the realm of patient empowerment and treatment success.

The impact of these global best practices can be illustrated by comparing regions on critical indicators such as wastage in cold chain management.

TABLE 1. Comparative Wastage Rates in Cold Chain Management

Region/Economy	Wastage Rate for Vaccines/Injectables	Source
Europe/US	<5%	WHO (2017); EMA (2018)
India (select states)	25–30%	MoHFW (2020); Deloitte (2021)
Sub-Saharan Africa	15–25%	UNICEF (2019); WHO (2017)
Latin America	10–15%	PAHO (2018)

This comparison underscores stark disparities. In Europe and the United States, robust infrastructure, harmonized regulation, and digital monitoring minimize wastage to below 5 percent. In contrast, emerging economies struggle with double-digit losses due to inadequate cold chain equipment, unreliable electricity, and logistical bottlenecks. India, despite being one of the world's largest producers of vaccines and injectables, still reports wastage of up to 30 percent in certain states, reflecting systemic weaknesses in distribution and last-mile storage. These data highlight not only the success of global best practices but also the urgency of adapting them to emerging markets where inefficiencies translate directly into reduced patient access and compromised health outcomes.

6. LESSONS FOR EMERGING MARKETS

Emerging markets differ from global leaders in infrastructure, regulation, and resources. India's supply chain remains fragmented, with Deloitte (2021) reporting that 70% of wholesalers lack adequate cold chain facilities. In Africa, power shortages and transport bottlenecks undermine cold chain reliability, while in Latin America, private distributors are strong but regulations remain inconsistent across countries.

TABLE 2. Global Adoption of Serialization and Traceability Measures

Region/Economy	Serialization/Traceability Adoption	Source
European Union	100% (mandatory since 2019)	EMA (2018)
United States	90% (Drug Supply Chain Security Act)	FDA (2019)
India	Limited, export-focused, pilot phase	CDSCO (2021)
Brazil	Partial, phased implementation	ANVISA (2020)
South Africa	Low, pilot programs ongoing	South African Health Review (2019)

This table illustrates the uneven adoption of serialization across regions. While Europe and the U.S. have achieved near-universal coverage, India and Brazil remain in partial or pilot phases, and Africa lags behind, though pilot projects suggest potential for digital leapfrogging. The key lesson is that phased adoption is necessary. Emerging economies cannot simply replicate European or U.S. models but must prioritize high risk categories such as oncology injectables and export markets, where incentives for compliance are strongest. Cold chain investments should begin with regional hubs, supported by IoT monitoring, before scaling nationally. Public Private partnerships, as seen in South Africa, can provide financial and operational support.

7. FINDINGS & DISCUSSION

The findings reveal clear patterns. Global best practices cluster around five domains; serialization, cold chain resilience, risk sharing partnerships, regulatory harmonization, and patient centric models that collectively improve efficiency, resilience, and safety. Their success in high income countries is supported by strong infrastructure, harmonized regulations, and financial capacity.

Emerging economies face significant challenges. Vaccine wastage rates of 25–30% in some Indian states (MoHFW, 2020), fragmented distributor networks lacking cold chain equipment (Deloitte, 2021), and inconsistent enforcement of serialization illustrate the systemic barriers. Africa's infrastructure gaps, including unreliable electricity for refrigeration, remain major obstacles. Latin America faces regulatory inconsistencies that hinder regional harmonization.

Yet opportunities exist. Digital tools such as IoT-enabled sensors, blockchain for serialization, and predictive analytics allow emerging economies to leapfrog traditional barriers. India's eVIN demonstrates that scalable digital monitoring is possible. Regional harmonization initiatives, modelled on FDA–EMA collaboration, could reduce duplication and build trust across markets. Public Private partnerships, like Gavi's vaccine distribution, demonstrate that risk sharing mechanisms can offset financial limitations.

Ultimately, adaptation rather than replication is required. Hybrid models that combine centralized oversight with regional spokes, supplemented by selective direct-to-patient delivery for high-value therapies, appear most viable for emerging markets.

8. CONCLUSION & RECOMMENDATIONS

This study concludes that global best practices in injectable formulations value chain management serialization, cold chain strengthening, risk-sharing/mitigation, regulatory harmonization, and patient centric models are essential for ensuring safety, efficiency, and resilience. However, their adoption in emerging markets requires phased implementation and careful adaptation.

Emerging economies should prioritize phased serialization, beginning with high-value injectables and export bound products. Cold chain investments should focus on regional hubs supported by IoT enabled monitoring before nationwide scaling. Risk sharing contracts and Public Private partnerships should be expanded to distribute liability and costs. Regulatory harmonization across regions, modelled on FDA–EMA collaboration, can improve oversight. Finally, patient centric models should be piloted in oncology and chronic disease therapies, where adherence and outcomes are critically linked to distribution integrity.

These reforms should not be seen as optional improvements but as strategic investments in healthcare equity. Strengthening the value chain for injectables reduces wastage, lowers costs, improves access, and enhances public confidence in healthcare systems. Future research must supplement these secondary findings with field-based studies involving distributors, regulators, and patients to validate and refine the framework for specific contexts.

REFERENCES

[1]. World Health Organization. Model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products. WHO Technical Report Series. Geneva: WHO; 2017. p. 1-34.
[2]. McKinsey & Company. Pharma logistics 2030: Securing cold chain integrity. New York: McKinsey; 2020. p. 11-27.
[3]. PwC. Reinventing pharma supply chains: Delivering value in a changing world. London: PwC; 2019. p. 44-61.
[4]. Deloitte. Indian pharmaceutical distribution: Unlocking value. Mumbai: Deloitte Insights; 2021. p. 1-32.
[5]. European Medicines Agency. Falsified Medicines Directive: Implementation and outcomes. London: EMA; 2018. p. 10-22.
[6]. Roche Holding AG. Annual report: Supply chain innovation in oncology. Basel: Roche; 2020. p. 78-85.
[7]. Pfizer Inc. Global logistics and supply chain report. New York: Pfizer; 2021. p. 24-31.
[8]. Novartis AG. Logistics whitepaper: Direct-to-hospital models in biologics. Basel: Novartis; 2020. p. 12-20.
[9]. Johnson & Johnson. Patient support programs and oncology delivery models. New Jersey: J&J; 2019. p. 30-42.
[10]. Ministry of Health and Family Welfare (MoHFW). National vaccine wastage assessment report. New Delhi: MoHFW; 2020. p. 12-25.
[11]. UNICEF. Strengthening immunization supply chains in Africa and Asia. New York: UNICEF; 2019. p. 5-19.
[12]. Pan American Health Organization (PAHO). Cold chain assessment in Latin America. Washington: PAHO; 2018. p. 90-104.
[13]. South African Health Review. Supply chain pooling in regional cold chain systems. Pretoria: Health Systems Trust; 2019. p. 140-55.
[14]. Rogers E. Diffusion of innovations. 5th ed. New York: Free Press; 2003. p. 1-38.
[15]. U.S. Food and Drug Administration. Drug Supply Chain Security Act (DSCSA) implementation guidance. Silver Spring: FDA; 2019. p. 18-25.
[16]. ANVISA. Serialization roadmap for Brazil's pharmaceutical sector. Brasília: Agência Nacional de Vigilância Sanitária; 2020. p. 8-16.